ReviewCurrent opinion in pediatrics2011
A second-generation pneumococcal conjugate vaccine for prevention of pneumococcal diseases in children.
Review in Current opinion in pediatrics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Pneumococcal vaccination during pregnancy for preventing infant infection.The Cochrane database of systematic reviews · 2015Pooled it
- Frequency-dependent selection can forecast evolution in Streptococcus pneumoniae.PLoS biology · 2020Article
- Challenges in the management of acute mastoiditis in children.Current infectious disease reports · 2015Article
- Pneumococcal vaccine and patients with pulmonary diseases.The American journal of medicine · 2014Review
- Nasopharyngeal carriage of individual Streptococcus pneumoniae serotypes during pediatric radiologically confirmed community acquired pneumonia following PCV7 introduction in Switzerland.BMC infectious diseases · 2013Article
- The pharmacological approach to the elderly COPD patient.Drugs & aging · 2013Review
- Pediatric invasive pneumococcal disease in the United States in the era of pneumococcal conjugate vaccines.Clinical microbiology reviews · 2012Review
- The status of invasive pneumococcal disease among children younger than 5 years of age in north-west Lombardy, Italy.BMC infectious diseases · 2012Article
- Acute bacterial meningitis in infants and children: epidemiology and management.Paediatric drugs · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
purpose of reviewA second-generation 13-valent pneumococcal conjugate vaccine (PCV13) was licensed and recommended for universal immunization of children through age 5 years in 2010. Its introduction is intended to address the residual burden of pneumococcal diseases that persists a decade after the introduction of PCV7. RECENT
findingsImmunization with PCV7 has resulted in a substantial decline in pneumococcal diseases caused by vaccine serotypes in both vaccinated and unvaccinated persons in the USA. However, an increase in disease due to nonvaccine serotypes, including empyema; the emergence of multidrug, including ceftriaxone, resistant serotype 19A strains; and the need for broader serotype coverage to address the global disease burden provides a rationale for a second-generation conjugate vaccine that includes serotypes 1, 3, 5, 6A, 7F and 19A. SUMMARY: This article reviews the lessons learned from a decade of experience with PCV7, the increasing problem of disease due to nonvaccine serotypes, and the likelihood of PCV13 to impact the residual disease burden. We contrast the potential differences in prevention of invasive pneumococcal disease compared with nonbacteremic pneumonia and acute otitis media. We conclude with the current recommendations for PCV13 providing a rationale for immunization through age 5 years to create both direct and indirect protection in the population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.